[Congressional Record Volume 167, Number 86 (Tuesday, May 18, 2021)]
[Senate]
[Page S2741]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]
SA 1515. Ms. ERNST submitted an amendment intended to be proposed by
her to the bill S. 1260, to establish a new Directorate for Technology
and Innovation in the National Science Foundation, to establish a
regional technology hub program, to require a strategy and report on
economic security, science, research, innovation, manufacturing, and
job creation, to establish a critical supply chain resiliency program,
and for other purposes; which was ordered to lie on the table; as
follows:
At the appropriate place, insert the following:
SEC. __. EXPANDING THE DOMESTIC PRODUCTION OF MEDICAL
SUPPLIES.
Title III of the Public Health Service Act is amended by
inserting after section 319F-4 (42 U.S.C. 247d-6e) the
following:
``SEC. 319F-5. EXPANDING THE DOMESTIC PRODUCTION OF MEDICAL
SUPPLIES.
``(a) In General.--The Secretary, in consultation with the
Secretary of Defense, shall award grants to drug, biological
product (including vaccines), device (including respiratory
protective devices), and other medical supply manufacturers
for the purpose of incentivizing such manufacturers to
manufacture such products domestically using advanced
manufacturing, and to ensure that the Nation is able to
retain or acquire necessary supplies to address critical
public health needs, including countermeasures required
during a pandemic or other public health emergency.
``(b) Eligible Products.--The Secretary, in consultation
with the Secretary of Defense, shall compile and update a
list of drugs, biological products (including vaccines),
devices (including respiratory protective devices), and other
medical supplies that are, or may become, critical supplies
in the event of a pandemic or public health emergency.
``(c) Eligibility.--To be eligible for a grant under this
section, a manufacturer shall submit an application to the
Secretary at such time, in such manner, and containing such
information as the Secretary may require, including the
applicant's plan for the advanced manufacturing,
domestically, of a product on the list under subsection (b).
``(d) Grant Awards.--A grant awarded under this section--
``(1) shall be used for the capital costs associated with
the installation of countermeasure manufacturing equipment
(including both final finished products and the related
critical components required for these products), including
the building and assembly of manufacturing equipment,
modifications to existing facilities to accommodate such
equipment, or expansion of existing facilities to accommodate
such equipment, in accordance with the advanced manufacturing
plan set forth in the application under subsection (c); and
``(2) shall be in amount not to exceed the amount
sufficient to cover up to 50 percent of the costs described
in paragraph (1).
``(e) Waiver of Certain Requirements.--The requirements of
section 75.323 of title 45, Code of Federal Regulations (or
any successor regulations) shall not apply with respect to a
grant awarded under this section.
``(f) Ongoing Monitoring.--The Secretary, in coordination
with the Secretary of Defense, shall establish and implement
procedures for the ongoing monitoring of the program under
this section to ensure that such program works toward the
goal of expanding domestic production of drugs, biological
products (including vaccines), devices (including respiratory
protective devices), and other medical supplies.
``(g) Reporting.--Not later than 180 days after the date of
the enactment of this section and annually thereafter, the
Secretary, in coordination with the Secretary of Defense,
shall submit to Congress a report on the program under this
section. Each such report shall include certification that
all funds appropriated for the purpose of carrying out this
section are used solely for such purpose.
``(h) Authorization of Appropriations.--To carry out this
section, there are authorized to be appropriated $250,000,000
for each of fiscal years 2022 through 2026.''.
______